Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cabaletta BioCABA +1.09%34 Equity-to-Asset is 0.70 as of Mar. 2026, which is 25% below its 10-year median of 0.93. GuruFocus rates CABA with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,416 Biotechnology companies, Cabaletta Bio ranks better than 52.19% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cabaletta Bio's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $103.31 Mil. Cabaletta Bio's Total Assets for the quarter that ended in Mar. 2026 was $148.15 Mil.
The historical rank and industry rank for Cabaletta Bio's Equity-to-Asset or its related term are showing as below:
CABA'
s Equity-to-Asset Range Over the Past 10 Years
Min: -249 Med: 0.93 Max: 0.98
Current: 0.7
During the past 9 years, the highest Equity to Asset Ratio of Cabaletta Bio was 0.98. The lowest was -249.00. And the median was 0.93.
CABA's Equity-to-Asset is ranked better than 52.19% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs CABA: 0.70
Cabaletta Bio (NAS:CABA) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cabaletta Bio Equity-to-Asset Related Terms
Cabaletta Bio Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Cabaletta Bio's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CABA vs SGMT, OVID, QTTB: Equity-to-Asset Comparison
For the Biotechnology subindustry, Cabaletta Bio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cabaletta Bio Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cabaletta Bio's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cabaletta Bio's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cabaletta Bio's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cabaletta Bio (CABA) has a Equity-to-Asset of 0.70 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cabaletta Bio and its competitors. This is 25% below median its historical median of 0.93. According to the industry distribution chart, Cabaletta Bio ranks #677 out of 1416 companies in the Biotechnology industry, placing it in the top 47.8%.
Is Cabaletta Bio's Equity-to-Asset too high?
Cabaletta Bio's current Equity-to-Asset of 0.70 is 25% below median its 10-year median of 0.93. The Biotechnology industry median Equity-to-Asset is 0.68. Cabaletta Bio's value of 0.70 is 2.9% above this industry median. Based on the distribution chart, Cabaletta Bio ranks #677 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cabaletta Bio has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cabaletta Bio's Equity-to-Asset compare to SGMT and OVID?
According to the Biotechnology industry distribution chart, Cabaletta Bio ranks #677 out of 1416 companies for Equity-to-Asset. This puts Cabaletta Bio in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Cabaletta Bio's value of 0.70 is 2.9% above this benchmark. While the company's 10-year median is 0.93 vs. the industry median of 0.68, Cabaletta Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cabaletta Bio's current Equity-to-Asset of 0.70 is 2.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cabaletta Bio and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cabaletta Bio's current Equity-to-Asset is 0.70, which is 25% below median its own 10-year median of 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cabaletta Bio stock overvalued right now?
Cabaletta Bio (CABA) has a current Equity-to-Asset of 0.70. The current Equity-to-Asset is 0.70, which is 25% below median its 10-year median of 0.93 and 2.9% above the Biotechnology industry median of 0.68. Cabaletta Bio's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cabaletta Bio (CABA), the current Equity-to-Asset is 0.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
34GF Score
Get the complete analysis for CABA
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CABA has been successfully added to your 
